Dec 15 (Reuters) - Mesoblast Ltd MSB.AX :
* PROVIDES TOPLINE RESULTS FROM PHASE 3 TRIAL OF REXLEMESTROCEL-L FOR ADVANCED CHRONIC HEART FAILURE
* NO REDUCTION IN RECURRENT NON-FATAL DECOMPENSATED HEART FAILURE EVENTS, WHICH WAS TRIAL'S PRIMARY ENDPOINT
* SIGNIFICANT REDUCTION IN PRE-SPECIFIED ENDPOINT OF CARDIAC DEATH
* REXLEMESTROCEL-L REDUCES MORTALITY BY MECHANISMS THAT ARE DISTINCT FROM THOSE OF EXISTING DRUGS